BCAX Annual CFF
$272.50 M
+$240.80 M+759.74%
01 December 2023
Summary:
As of January 23, 2025, BCAX annual cash flow from financing activities is $272.50 million, with the most recent change of +$240.80 million (+759.74%) on December 1, 2023. During the last 3 years, it has risen by +$240.80 million (+759.74%). BCAX annual CFF is now at all-time high.BCAX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BCAX Quarterly CFF
$334.13 M
0.00%
30 September 2024
Summary:
As of January 23, 2025, BCAX quarterly cash flow from financing activities is $334.13 millionOver the past year, it has increased by +$294.23 million (+737.39%). BCAX quarterly CFF is now at all-time high.BCAX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BCAX TTM CFF
$334.13 M
0.00%
30 September 2024
Summary:
As of January 23, 2025, BCAX TTM cash flow from financing activities is $334.13 millionOver the past year, it has increased by +$294.23 million (+737.39%). BCAX TTM CFF is now at all-time high.BCAX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BCAX Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +759.7% | +737.4% | +737.4% |
| 3 y3 years | +759.7% | +737.4% | +737.4% |
| 5 y5 years | +759.7% | +737.4% | +737.4% |
BCAX Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +759.7% | at high | +737.4% | at high | +737.4% |
| 5 y | 5-year | at high | +759.7% | at high | +737.4% | at high | +737.4% |
| alltime | all time | at high | +759.7% | at high | +737.4% | at high | +737.4% |
Bicara Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $334.13 M(+737.4%) | $334.13 M(+737.4%) |
| Dec 2023 | $272.50 M | - | - |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2023 | - | $39.90 M | $39.90 M |
| Dec 2022 | $31.70 M | - | - |
FAQ
- What is Bicara Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Bicara Therapeutics?
- What is Bicara Therapeutics annual CFF year-on-year change?
- What is Bicara Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Bicara Therapeutics?
- What is Bicara Therapeutics quarterly CFF year-on-year change?
- What is Bicara Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Bicara Therapeutics?
- What is Bicara Therapeutics TTM CFF year-on-year change?
What is Bicara Therapeutics annual cash flow from financing activities?
The current annual CFF of BCAX is $272.50 M
What is the all time high annual CFF for Bicara Therapeutics?
Bicara Therapeutics all-time high annual cash flow from financing activities is $272.50 M
What is Bicara Therapeutics annual CFF year-on-year change?
Over the past year, BCAX annual cash flow from financing activities has changed by +$240.80 M (+759.74%)
What is Bicara Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of BCAX is $334.13 M
What is the all time high quarterly CFF for Bicara Therapeutics?
Bicara Therapeutics all-time high quarterly cash flow from financing activities is $334.13 M
What is Bicara Therapeutics quarterly CFF year-on-year change?
Over the past year, BCAX quarterly cash flow from financing activities has changed by +$294.23 M (+737.39%)
What is Bicara Therapeutics TTM cash flow from financing activities?
The current TTM CFF of BCAX is $334.13 M
What is the all time high TTM CFF for Bicara Therapeutics?
Bicara Therapeutics all-time high TTM cash flow from financing activities is $334.13 M
What is Bicara Therapeutics TTM CFF year-on-year change?
Over the past year, BCAX TTM cash flow from financing activities has changed by +$294.23 M (+737.39%)